INDIAN BIOPHARMA INDUSTRY GROWING AT 12% CROSSES ₹ 22,000 CRORE
BioSpectrum Top 20 Biopharma Special
The Indian Biopharma Industry with over 300 companies is growing at 12 per cent growth against the pharma industry growth which is passing through tough situation postGST, ban on manufacture, sale and distribution of over 340 fixed dose combination (FDC) drugs. For the year 2018-19 the Biopharma Industry crossed Rs 22,124 crore over previous year’s revenue of Rs 18,290 core with exports comprising of Rs 14,423 crore in 2018-19 witnessing growth over last year’s exports of 13,925 crore.
The BioSpectrum India edition was launched in March 2003 and is India's first comprehensive biotech business monthly magazine. It provides comprehensive coverage of the exciting happenings in life sciences, which include BioPharma, BioAgriculture, BioInformatics, BioIndustrial, BioSuppliers and BioServices and show cases the emerging Indian entrepreneurships in biotech industry. In a short time BioSpectrum has emerged as the most preferred platform to engage the life sciences industry in India and Asia Pacific. It is also widely accepted by research and academia community. Top key policy makers in the Central and state government use the magazine as a platform to reach out the Indian Biotech Industry. BioSpectrum has columns by Indian's top policy makers, biotechnology professionals, scientists and NGOs. Readers of BioSpectrum are from among the key Policy Makers, Key Executives and the Influencer's in Biotechnology, Pharmaceutical Companies, Research Heads of Clinical Research, Clinical Trials and Contract Mfg Organizations, Educational Institutes, Consultants, Fund Managers etc
